Last reviewed · How we verify

NCT05287633

Proton Pump Inhibitors Effects on Dyspepsia During Ramadan Fasting

Completed Phase 1, PHASE2 Last updated 25 February 2025
What this trial tests

Phase 1, PHASE2 trial testing Esomeprazole in Dyspepsia in 500 participants. Completed in 30 December 2024.

Timeline
20 January 2020
Primary endpoint
15 December 2020
30 December 2024

Quick facts

Lead sponsorUniversity of Monastir
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment500
Start date20 January 2020
Primary completion15 December 2020
Estimated completion30 December 2024
Sites1 location across Tunisia

Drugs / interventions tested

Conditions studied

Sponsor

University of Monastir

Who can join

18 and older, any sex, with Dyspepsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

evaluate the interest of proton pump inhibitors in subjects with or with GI symptoms who intend to observe fasting in Ramadan. The investigators will compare the effectiveness of proton pump inhibitors to prevent or reduce the signs of dyspepsia during Ramadan compared to placebo.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Randomized trial of the effect of esomeprazole on functional dyspepsia during Ramadan fasting.
    Hadrich S, Lamti F, Trabelsi I, Dhaoui R, et al · · 2025 · PMID 41120363 · DOI 10.1038/s41598-025-17532-x

Verify or expand the search:

Other trials of Esomeprazole

Trials testing the same drug.

Other recruiting trials for Dyspepsia

Currently open trials in the same condition.

Other University of Monastir trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05287633.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing